tiprankstipranks
Advertisement
Advertisement
ProQR Sets April 8 Virtual Investor Event to Spotlight Axiomer RNA Editing Pipeline
PremiumCompany AnnouncementsProQR Sets April 8 Virtual Investor Event to Spotlight Axiomer RNA Editing Pipeline
29d ago
ProQR Therapeutics Faces Heightened Activist Investor Pressure and Governance Uncertainty
Premium
Company Announcements
ProQR Therapeutics Faces Heightened Activist Investor Pressure and Governance Uncertainty
1M ago
ProQR Posts 2025 Results as Axiomer RNA Editing Pipeline Advances and Cash Runway Extends to Mid-2027
Premium
Company Announcements
ProQR Posts 2025 Results as Axiomer RNA Editing Pipeline Advances and Cash Runway Extends to Mid-2027
1M ago
ProQR Therapeutics Plans Board Changes as Co-Founder and Director Exit at 2026 AGM
PremiumCompany AnnouncementsProQR Therapeutics Plans Board Changes as Co-Founder and Director Exit at 2026 AGM
2M ago
ProQR Therapeutics directors Dinko Valerio, Alison Lawton to depart
Premium
The Fly
ProQR Therapeutics directors Dinko Valerio, Alison Lawton to depart
2M ago
ProQR Reports Positive AX-0810 Phase 1 Data, Advances Rett and MASH Candidates, and Outlines 2026 Pipeline Plans
Premium
Company Announcements
ProQR Reports Positive AX-0810 Phase 1 Data, Advances Rett and MASH Candidates, and Outlines 2026 Pipeline Plans
3M ago
ProQR Therapeutics reports Q3 (EUR 0.10) vs (EUR 0.10) last year
PremiumThe FlyProQR Therapeutics reports Q3 (EUR 0.10) vs (EUR 0.10) last year
6M ago
ProQR Positioned for Growth: Strategic Advancements and Clinical Milestones in RNA Editing
Premium
Ratings
ProQR Positioned for Growth: Strategic Advancements and Clinical Milestones in RNA Editing
6M ago
ProQR Advances AX-0810 into Clinical Trials for Cholestatic Diseases
Premium
Company Announcements
ProQR Advances AX-0810 into Clinical Trials for Cholestatic Diseases
6M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100